文献速递神经肿瘤小儿神经外科与脑积水

儿童及青少年高级别胶质瘤的MMR缺陷:多组学分析

Unveiling MMR deficiency in pediatric and AYA high-grade gliomas: insights from multiomic profiling.
PubMed 文献 · J Neurooncol · 2025-10-15

该研究回顾性分析印度北部100例CNS WHO 4级弥漫性高级别胶质瘤,免疫组化显示11%存在MMR蛋白完全缺失,另5%部分缺失。MMR缺陷病例中56.25%为儿童,43.75%为青少年/青年,WES显示高频超突变及POLE相关特征,但免疫标志物与MMR状态无显著关联。

要点

  • 儿童及青少年高级别胶质瘤中MMR缺陷检出率为11%(完全缺失)和5%(部分缺失)。
  • MMR缺陷病例以PMS2缺失最常见(62.5%),且多伴超突变和POLE相关特征。
  • 建议对儿童及AYA高级别胶质瘤常规行MMR检测,以指导诊断、遗传咨询及免疫治疗考量。

核心结论

  • 儿童及AYA高级别胶质瘤中MMR缺陷患病率为11%(IHC完全缺失),超突变主要由MMR和聚合酶通路序贯缺陷驱动。

研究设计与样本

  • 回顾性分析2016–2024年印度北部三级中心100例CNS WHO 4级弥漫性高级别胶质瘤,采用IHC检测MMR蛋白,并对部分MMR缺陷病例行WES、TMB、突变特征和全基因组甲基化分析。

主要发现

  • 11%(11/100)病例至少一种MMR蛋白完全缺失,另5%(5/100)部分缺失。
  • PMS2是最常缺失的蛋白(62.5%),其次为MSH2、MLH1和MSH6。
  • MMR缺陷病例中56.25%为儿童(中位年龄8岁),43.75%为AYA(中位年龄26岁)。
  • 多核巨细胞存在与MMR状态显著相关。
  • WES显示4/6例检测病例为超突变(TMB>100 mutations/Mb),66%具有POLE相关特征。

关键数值与推荐

  • MMR缺陷定义为IHC显示至少一种MMR蛋白完全缺失,部分缺失另计。
  • 超突变定义为TMB>100 mutations/Mb(WES检测)。

临床怎么用

  • 对儿童及AYA高级别胶质瘤患者应常规行MMR免疫组化检测。
  • MMR缺陷结果有助于遗传咨询和免疫治疗考虑。

局限性

  • 回顾性单中心研究,样本量有限(100例),WES仅检测6例。
  • PD-L1、CTLA-4和CD8表达与MMR状态无显著关联,免疫微环境特征需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-grade gliomas (HGGs) in children and adolescents/young adults (AYAs) are aggressive tumors with a poor prognosis. A subset is driven by constitutional mismatch repair deficiency (CMMRD), an inherited cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. Despite its clinical relevance, data on MMR deficiency (MMR-D) in Indian populations are scarce. METHODS: We retrospectively analyzed 100 cases of CNS WHO grade 4 diffuse HGGs (2016–2024) from a tertiary care center in North India. MMR protein expression was assessed by immunohistochemistry (IHC). With selected MMR-D cases further analyzed by Whole-exome sequencing (WES), tumor mutational burden (TMB), mutational signatures, and genome-wide methylation profiling. Immune markers, including PD-L1, CTLA-4, CD8, and p53, were also evaluated. RESULTS: Complete loss of at least one MMR protein was observed in 11% (11/100) cases, while another 5% (5/100) of cases showed partial loss PMS2 was the most frequently lost protein (62.5%), followed by MSH2, MLH1, and MSH6. Among MMR-D cases, 56.25% were pediatric and 43.75% were AYA, with median ages of 8 and 26 years, respectively. A significant correlation was found between the presence of giant cells and MMR status. WES revealed ultra-hypermutation (TMB > 100 mutations/Mb) in 4/6 tested cases and polymerase (POLE)-associated signatures in 66%. Concurrent mutations in TP53, NF1, and ATRX were frequently observed. Despite high TMB, PD-L1, CTLA-4, and CD8 expression showed no significant association with MMR status CONCLUSION: Our study identified a 11% prevalence of MMR-D in CNS WHO grade 4 HGGs using IHC, with hypermutation predominantly driven by sequential MMR and polymerase pathway defects. These tumors exhibit unique molecular profiles distinct from adult sporadic gliomas and warrant routine MMR testing in pediatric and AYA patients for accurate diagnosis, genetic counseling, and consideration of immunotherapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Bhardwaj S, Singh J, Singh S, et al. Unveiling MMR deficiency in pediatric and AYA high-grade gliomas: insights from multiomic profiling. J Neurooncol. 2025. PMID: 41094292. doi:10.1007/s11060-025-05261-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。